Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
David BarinbergMikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, D-91054, Erlangen, Germany.ORCID 0000-0003-4702-0749
Heidi SebaldMikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, D-91054, Erlangen, Germany.
Tobias GoldMikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, D-91054, Erlangen, Germany.ORCID 0009-0000-6056-7496
Baplu RaiMikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, D-91054, Erlangen, Germany.
Daniel RadtkeInfektionsbiologische Abteilung, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, D-91054, Erlangen, Germany.ORCID 0000-0003-3241-4542
Dominik LermChair of Medical Informatics, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, D-91058, Erlangen, Germany.
David VoehringerInfektionsbiologische Abteilung, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, D-91054, Erlangen, Germany.
Jonathan JantschInstitute for Medical Microbiology, Immunology, and Hygiene and Center for Molecular Medicine Cologne, University Hospital Cologne and Faculty of Medicine, University of Cologne, Köln, D-50935, Germany.
Stefan WirtzFAU Profile Center Immunomedicine (FAU I-Med), D-91054, Erlangen, Germany.ORCID 0000-0001-6936-7431
Alina Ulezko AntonovaDepartment of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, 63110, USA.
Marco ColonnaDepartment of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, 63110, USA.ORCID 0000-0001-5222-4987
Christian Bogdan *Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, D-91054, Erlangen, Germany. christian.bogdan@uk-erlangen.de.ORCID 0000-0002-2300-0631
Deutsche Forschungsgemeinschaft (DFG) BO 996/5-1 and 5-2Deutsche Forschungsgemeinschaft (DFG) BO996/7-1Deutsche Forschungsgemeinschaft (DFG) CRC1181,C04Deutsche Forschungsgemeinschaft (DFG) RTG 2740,A2Deutsche Forschungsgemeinschaft (DFG) RTG 2740,A4Deutsche Forschungsgemeinschaft (DFG) RTG 2740,A6Deutsche Forschungsgemeinschaft (DFG) RTG 2740,A7Deutsche Forschungsgemeinschaft (DFG) RTG 2740,B2Deutsche Forschungsgemeinschaft (DFG) SCHL 615/1-1 and 1-2Deutsche Forschungsgemeinschaft (DFG) SCHL615/3-1Interdisciplinary Center for Clinical of Research (IZKF) of the Universitätsklinikum Erlangen A87
6 · The paper itself
Abstract
Eosinophils exhibit antimicrobial, cytotoxic and immunoregulatory effects, but our knowledge of their transcriptional and functional heterogeneity is still limited, especially in non-intestinal tissues. Here, we used a mouse model of chronic cutaneous inflammation elicited by the protozoan pathogen Leishmania mexicana to investigate the function and transcriptional dynamics of skin eosinophils. Infection of C57BL/6 mice triggered local and systemic eosinophilia that was driven by type 2 innate lymphoid cells and interleukin-5. Genetic and pharmacological eosinophil depletion led to an enhanced Th1 response, polarization towards M1-like macrophages and resolution of clinical disease, despite an unexpected simultaneous upregulation of IL-4. Single-cell transcriptomics revealed a skin-imprinted trajectory of inflammatory eosinophils that strongly expressed the glucose transporter Slc2a3 (GLUT3) These eosinophils impeded the function of Th1 cells by forming a competitive metabolic niche through preferential glucose uptake. Our findings uncover an inflammatory, metabolically reprogrammed eosinophil population that promotes chronic skin inflammation by limiting protective T cell responses.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Metabolically reprogrammed eosinophils impair T cell immunity and cause chronic skin infection. · full record | OpenQuestion